SOOLANTRA Drug Patent Profile
✉ Email this page to a colleague
When do Soolantra patents expire, and when can generic versions of Soolantra launch?
Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.
This drug has seventy-seven patent family members in twenty-eight countries.
The generic ingredient in SOOLANTRA is ivermectin. There are five drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ivermectin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Soolantra
A generic version of SOOLANTRA was approved as ivermectin by EDENBRIDGE PHARMS on October 24th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SOOLANTRA?
- What are the global sales for SOOLANTRA?
- What is Average Wholesale Price for SOOLANTRA?
Summary for SOOLANTRA
International Patents: | 77 |
US Patents: | 12 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Clinical Trials: | 6 |
Drug Prices: | Drug price information for SOOLANTRA |
Drug Sales Revenues: | Drug sales revenues for SOOLANTRA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SOOLANTRA |
What excipients (inactive ingredients) are in SOOLANTRA? | SOOLANTRA excipients list |
DailyMed Link: | SOOLANTRA at DailyMed |
Recent Clinical Trials for SOOLANTRA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
Catawba Research, LLC | Phase 3 |
Zydus Worldwide DMCC | Phase 3 |
Pharmacology for SOOLANTRA
Drug Class | Antiparasitic Pediculicide |
Paragraph IV (Patent) Challenges for SOOLANTRA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
SOOLANTRA | Cream | ivermectin | 1% | 206255 | 1 | 2016-12-30 |
US Patents and Regulatory Information for SOOLANTRA
SOOLANTRA is protected by twelve US patents.
Patents protecting SOOLANTRA
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of inflammatory lesions of rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Treatment of papulopustular rosacea with ivermectin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SOOLANTRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SOOLANTRA
See the table below for patents covering SOOLANTRA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2916704 | TRAITEMENT DES LESIONS INFLAMMATOIRES CAUSEES PAR LA ROSACEE A L'IVERMECTINE (TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA WITH IVERMECTIN) | ⤷ Sign Up |
South Korea | 101187231 | ⤷ Sign Up | |
Russian Federation | 2016103715 | ЛЕЧЕНИЕ ПАПУЛОПУСТУЛЕЗНОЙ РОЗАЦЕА ИВЕРМЕКТИНОМ | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2004093886 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SOOLANTRA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1620113 | 2015/046 | Ireland | ⤷ Sign Up | PRODUCT NAME: IVERMECTIN; NAT REGISTRATION NO/DATE: PA0590/028/001 20150424; FIRST REGISTRATION NO/DATE: MA117/01101 20150402 |
1620113 | 300756 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN DE BEHANDELING VAN ROSACEA; NATIONAL REGISTRATION NO/DATE: RVG 115310 20150504; FIRST REGISTRATION: MT MA117/01101 20150402 |
1620113 | 56/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: IVERMECTIN; NAT. REGISTRATION NO/DATE: 136170 20150602; FIRST REGISTRATION: MT MA 117/01101 20150402 |
1620113 | C20150035 00175 | Estonia | ⤷ Sign Up | PRODUCT NAME: IVERMEKTIIN;REG NO/DATE: EE 872915 08.06.2015 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |